SecBot SecBot

XENE drug pipeline

$40.48
−1.3% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.0%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
4
1 mixed · 3 neutral
Phase 3 trials
2
0 with results posted

Upcoming catalysts

1 dated
  1. Jan 2027
    azetukalner
    Phase 3 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseFiled/NDA under FDA review
Time to marketIf the FDA accepts the NDA for filing (expected mid-November 2026), a standard 10-month review would set a PDUFA target action date around mid-2027. The drug could potentially launch in the second half of 2027 if approved.

azetukalner Updated Nov 5

What to watch

The next near-term catalyst is the FDA's 60-day filing acceptance decision on the azetukalner NDA, expected around mid-November 2026. If accepted, a PDUFA date (likely standard review, ~10 months, pointing to mid-2027) would be set. The Q3 2026 earnings call on Nov 9 may also provide updates on the psychiatry program pause and the X-TOLE3/X-ACKT epilepsy trials. The psychiatry safety overhang and the stock's 46% decline from its 52-week high mean the FDA filing acceptance and any clarity on the depression program restart timeline are the key swing factors.

Bull case
  • The Phase 3 X-TOLE2 trial delivered strong results: 53.2% median seizure reduction at 25mg vs 10.4% for placebo (p<0.0001), one of the largest placebo-adjusted efficacy signals seen in recent epilepsy trials.
  • The NDA for focal seizures was submitted to the FDA on September 17, 2026, backed by over 1,500 patient-years of epilepsy safety data across two positive trials.
  • Analyst consensus is Strong Buy (11 Strong Buy, 12 Buy, 2 Hold) with a mean price target of $71.75, implying 83% upside from the current $39.19 price.
Bear case
  • The psychiatry program (MDD and bipolar depression) was paused in September 2026 after neuropsychiatric adverse events including psychosis were observed, which wiped 30% off the stock in a single day and casts a shadow over the broader azetukalner safety profile.
  • Deutsche Bank downgraded the stock from Buy to Hold on Sept 18, 2026, and several large institutional holders trimmed or exited in Q2 2026, including Wellington Management (trimmed 70.5%), Holocene Advisors (exited), and Jennison Associates (near-exit, trimmed 84.2%).
  • Elevated short-sale volume (z-score 1.51 vs the stock's own history) suggests bearish positioning around the stock.
● neutral
Impact
PhasePhase 1 completed; advancing to Phase 2
Time to marketXEN1120 has completed Phase 1 and is advancing to Phase 2 proof-of-concept studies expected in H1 2027. Even if Phase 2 succeeds, the drug would still need Phase 3 trials and FDA review, putting potential approval several years away (likely 2029-2031 at the earliest).

XEN1120 Updated Nov 12

What to watch

Watch for the initiation of Phase 2 proof-of-concept studies for XEN1120 in acute pain, expected in H1 2027. The more immediate catalysts for Xenon stock are the December 2026 X-NOVA2 MDD topline readout for azetukalner and the FDA's review of the azetukalner NDA for focal seizures. XEN1120 is too early-stage to drive material share-price moves on its own.

Bull case
  • Positive Phase 1 data showed XEN1120 achieved plasma levels predictive of analgesic effects and was generally well-tolerated, supporting advancement to Phase 2.
  • XEN1120 is a non-opioid pain candidate targeting a large market opportunity amid growing regulatory and societal pressure to reduce opioid prescribing.
  • Xenon has a deep cash position of $1.15B (as of September 30, 2026) providing runway into 2029, ample to fund XEN1120's Phase 2 development without near-term dilution risk.
Bear case
  • XEN1120 is an early-stage, pre-revenue asset with no approved products; Phase 2 proof-of-concept studies in acute pain have not yet begun and could fail to show efficacy.
  • The acute pain market is highly competitive with many established generic and branded non-opioid analgesics, making differentiation difficult even if Phase 2 succeeds.
  • XEN1120 is a small part of Xenon's pipeline; the company's stock is driven primarily by azetukalner (epilepsy NDA and depression Phase 3 readout), so XEN1120-specific news is unlikely to move shares materially.
● neutral
Impact
PhasePhase 1 completed; advancing to Phase 2
Time to marketXEN1701 has just completed Phase 1 and is advancing to Phase 2 proof-of-concept studies. Assuming successful Phase 2 and Phase 3 trials, potential approval would be several years away, likely in the 2030s at the earliest.

XEN1701 Updated Nov 12

What to watch

XEN1701 is an early-stage (Phase 1 completed) non-opioid pain candidate at Xenon, which is far from a binary catalyst. The next event to watch is initiation of Phase 2 proof-of-concept studies in acute pain, which management indicated is planned but has not given a specific date. The much larger near-term catalyst for XENE stock is the Phase 3 X-NOVA2 depression data for lead asset azetukalner expected in December 2026, and the FDA review of the azetukalner NDA for focal seizures (submitted September 2026). XEN1701 itself is unlikely to drive material share price movement in the next 12 months.

Bull case
  • Phase 1 data showed XEN1701 achieved desired Nav1.7 receptor occupancy in both peripheral and central nervous systems with good tolerability and no notable autonomic cardiovascular effects, supporting advancement to Phase 2.
  • Preclinical data in cynomolgus monkeys demonstrated that >75% Nav1.7 receptor occupancy produced ~85-100% pain reduction in capsaicin-evoked heat pain models, suggesting strong target engagement.
  • XEN1701 is a non-opioid pain candidate addressing a large unmet need and large market opportunity in acute pain, especially given growing regulatory and societal pressure to reduce opioid prescribing.
Bear case
  • XEN1701 is an early-stage asset (Phase 1 just completed) with no guarantee of success in Phase 2 proof-of-concept studies. Nav1.7 inhibitors have a mixed history in pain drug development, with several prior candidates failing to show efficacy in human trials despite strong preclinical data.
  • XEN1701 is a small part of Xenon's pipeline; the company's value is dominated by azetukalner (XEN1101) for epilepsy and depression. The September 2026 psychiatry trial enrollment pause and subsequent 30% stock drop show how binary the lead asset is for XENE's valuation.
  • Xenon faces competition from Vertex's suzetrigine (already approved and commercializing as a non-opioid pain drug) and other Nav1.7/1.8 inhibitors in development.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

XEN1720 Updated Nov 12

What to watch

XEN1720 is not a publicly disclosed development candidate. Xenon's pipeline is focused on azetukalner (epilepsy NDA submitted, depression Phase 3 data due December 2026) and two pain candidates (XEN1701, XEN1120) advancing to Phase 2. Until Xenon formally discloses XEN1720 as a named program, there is no actionable catalyst to track for this molecule.

Bull case
  • Xenon has a strong cash position of roughly $1.25 billion (as of Q2 2026), funding operations into 2029, which supports early discovery work including potential programs like XEN1720.
  • Xenon's expertise in ion channel modulation and its validated Kv7 platform (azetukalner) could extend to novel preclinical assets.
  • CEO Ian Mortimer and CFO Thomas Kelly made open-market insider purchases totaling over $1.6 million in September 2026, signaling confidence in the company's pipeline broadly.
Bear case
  • XEN1720 has zero public presence: no clinical trials, no SEC filing mentions, no press releases, and no pipeline listing. It may not be an active development program at all.
  • Xenon's lead asset azetukalner faces binary risk: Phase 3 X-NOVA2 depression data is due December 2026, and a prior safety-related setback in the depression program has raised investor concerns.
  • The company raised $650 million in a March 2026 public offering, diluting existing shareholders, and reported a Q3 2026 net loss of $110 million.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Jul 1, 2026azetukalnerNDA filed+1.0%+17.6%

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
azetukalnerAn Open-Label Study of Azetukalner in Major Depressive DisorderPhase 3Active not recruiting460Jan 2027
azetukalnerA Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresPhase 3Completed380Jan 12, 2026
azetukalnerA Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderPhase 2Completed · results168Sep 18, 2023